Publications by authors named "David Groheux"

Claim this Profile
[
[F]-Labeled Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography in Staging and Restaging Patients With Breast Cancer.
David Groheux, Sofia C Vaz, Lioe-Fee de Geus-Oei, Elizabeth H Dibble, Gary A Ulaner

J Clin Oncol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FDG-PET/CT and Multimodal Machine Learning Model Prediction of Pathological Complete Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.
David Groheux, Loïc Ferrer, Jennifer Vargas, Antoine Martineau, Adrien Borgel

Cancers (Basel)· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant therapy in HER2-positive breast cancer and interim PET.
Elif Hindié, David Groheux

Lancet· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Editorial Commentary: Should "heterogeneous response" be considered as new category for assessing treatment response in patients with breast cancer?
Sofia C Vaz, David Groheux, Thiemo van Nijnatten, Lidija Antunovic, Fatima Cardoso

Eur J Nucl Med Mol Imaging· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Role of [F]FDG PET/CT in patients with invasive breast carcinoma of no special type: Literature review and comparison between guidelines.
David Groheux, Sofia C Vaz, Philip Poortmans, Ritse M Mann, Gary A Ulaner

Breast· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
J
Joint EANM-SNMMI guidelines on the role of 2-[F]FDG PET/CT in no special type breast cancer: differences and agreements with European and American guidelines.
David Groheux, Sofia C Vaz, Gary A Ulaner, Gary J R Cook, John Patrick Pilkington Woll

Eur J Nucl Med Mol Imaging· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
J
Joint EANM-SNMMI guideline on the role of 2-[F]FDG PET/CT in no special type breast cancer : (endorsed by the ACR, ESSO, ESTRO, EUSOBI/ESR, and EUSOMA).
Sofia C Vaz, John Patrick Pilkington Woll, Fatima Cardoso, David Groheux, Gary J R Cook

Eur J Nucl Med Mol Imaging· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quarter-Century Transformation of Oncology: Positron Emission Tomography for Patients with Breast Cancer.
Gary A Ulaner, Sofia Carrilho Vaz, David Groheux

PET Clin· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Breast Cancer Systemic Staging (Comparison of Computed Tomography, Bone Scan, and 18F-Fluorodeoxyglucose PET/Computed Tomography).
David Groheux

PET Clin· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient Selection for Internal Mammary Node Irradiation: Lymphoscintigraphy Can Help.
Elif Hindié, David Groheux

J Clin Oncol· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FDG-PET/CT for Primary Staging and Detection of Recurrence of Breast Cancer.
David Groheux

Semin Nucl Med· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Negative Relationship between Post-Treatment Stromal Tumor-Infiltrating Lymphocyte (TIL) and Survival in Triple-Negative Breast Cancer Patients Treated with Dose-Dense Dose-Intense NeoAdjuvant Chemotherapy.
Sylvie Giacchetti, Lilith Faucheux, Charlotte Gardair, Caroline Cuvier, Anne de Roquancourt, David Groheux

Cancers (Basel)· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Letter to the Editor: PET/CT in Locally Advanced Breast Cancer: Time for a Guideline Change?
David Groheux, Elif Hindié, Marc Espié, Gary A Ulaner

J Natl Compr Canc Netw· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evidence-Based Best Practices: 18F-FDG PET Staging of Newly Diagnosed Breast Cancer.
Gary A Ulaner, Heather A Jacene, Ashwin Singh Parihar, David Groheux

Clin Nucl Med· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Breast cancer: initial workup and staging with FDG PET/CT.
David Groheux, Elif Hindie

Clin Transl Imaging· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FDG-PET/CT Imaging in Breast Cancer Patients with Clinical Stage IIB or Higher : Commentary on "Overuse of Preoperative Staging of Patients Undergoing Neoadjuvant Chemotherapy for Breast Cancer" by Marissa K. Srour et al.
David Groheux, Elif Hindié

Ann Surg Oncol· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Good clinical practice recommendations for the use of PET/CT in oncology.
Pierre-Yves Salaün, Ronan Abgral, Olivier Malard, Solène Querellou-Lefranc, Gilles Quere, David Groheux

Eur J Nucl Med Mol Imaging· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interim [F]Fluorodeoxyglucose-Positron Emission Tomography During Neoadjuvant Therapy in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.
Elif Hindié, David Groheux

J Clin Oncol· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Update of the recommendations of good clinical practice for the use of PET in oncology].
Pierre-Yves Salaün, Ronan Abgral, Olivier Malard, Solène Querellou-Lefranc, Gilles Quere, David Groheux

Bull Cancer· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor metabolism assessed by FDG-PET/CT and tumor proliferation assessed by genomic grade index to predict response to neoadjuvant chemotherapy in triple negative breast cancer.
David Groheux, L Biard, J Lehmann-Che, L Teixeira, F A Bouhidel

Eur J Nucl Med Mol Imaging· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Role of Fludeoxyglucose in Breast Cancer: Treatment Response.
David Groheux

PET Clin· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Now Is the Time to Use F-FDG PET/CT to Optimize Neoadjuvant Treatment in Triple-Negative Breast Cancer!
David Groheux

J Nucl Med· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FDG-PET/CT and molecular markers to predict response to neoadjuvant chemotherapy and outcome in HER2-negative advanced luminal breast cancers patients.
Patricia de Cremoux, Lucie Biard, Brigitte Poirot, Philippe Bertheau, Luis Teixeira, David Groheux

Oncotarget· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FDG-PET/CT for systemic staging of patients with newly diagnosed breast cancer.
David Groheux

Eur J Nucl Med Mol Imaging· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FDG PET and FES PET Predict PFS on Endocrine Therapy-Letter.
David Groheux, François Bénard

Clin Cancer Res· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis